Case study date
2025
Aim:
To develop the technical capabilities that can generate tailored electronic product information (ePI) for prescribed medication and understand stakeholder views on the personalised information.
Patients in England are dispensed more than one billion prescribed medicines per year, and a large proportion of patients do not take their medication as intended. There is potential to improve patient experience and outcomes by providing access to trusted, up-to-date, tailored information regarding their prescribed medication in a digital format.
The team will establish a prototype secure data environment (SDE) innovation test environment and create a ‘living lab’. This will assess views of stakeholders (patients, professionals, the public, academics, innovators, and policy leaders) on perceived benefits, barriers, feasibility, uptake, and sustainability of personalised labelling information.
Potential public benefits:
- Improved patient outcomes (experience, quality and safety of care).
- Provide patients with more relevant information for the medication they have been prescribed.
- Improved patient/carer trust in programmes harnessing data for research.
Other project benefits include:
- Potential decrease in repeat healthcare professional (HCP) medicines-related visits due to patients having more relevant and focused digital information about their medicines.
- Potential reduction in hospital admissions due to adverse events / medicines being taken incorrectly, which in turn could reduce demand and costs.
- More specific medicines information to support HCPs during patient interactions.
More information is available on the Pfizer website.